Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
GeoVax Labs, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of human vaccines for infectious diseases and cancer immunotherapy. The company operates within the biotechnology and life sciences industries, with an emphasis on vaccines that address large unmet medical needs. GeoVax does not currently generate commercial product revenue and is primarily funded through a combination of government grants, public offerings, and strategic partnerships.
The company’s core value proposition centers on its proprietary Modified Vaccinia Ankara–Virus-Like Particle (MVA‑VLP) vaccine platform, designed to induce both humoral and cellular immune responses. GeoVax was founded in 2001 and has evolved from early HIV vaccine research into a broader infectious disease and oncology-focused vaccine developer, expanding its pipeline to include COVID‑19, Ebola, Sudan virus, Marburg virus, and cancer immunotherapy candidates.
Business Operations
GeoVax’s operations are organized around vaccine research and development rather than traditional operating segments. Its primary business activities include preclinical research, clinical trials, regulatory engagement, and manufacturing coordination through third parties. The company’s development programs are largely supported by non-dilutive funding from U.S. government agencies, including contracts and grants associated with biodefense and pandemic preparedness initiatives.
The company controls and develops its proprietary MVA‑VLP vaccine platform, which underpins multiple product candidates. GeoVax operates without in-house commercial manufacturing, relying instead on contract development and manufacturing organizations. The company conducts its operations primarily in the United States, with clinical and research collaborations extending internationally depending on trial location and disease focus.
Strategic Position & Investments
GeoVax’s strategy is centered on advancing late-stage clinical assets and positioning its platform for government procurement, global health partnerships, and potential licensing or commercialization agreements. Growth initiatives include advancing its COVID‑19 vaccine candidate as a next-generation booster, progressing filovirus vaccines under government-sponsored programs, and expanding its oncology immunotherapy pipeline.
The company has historically secured significant funding through U.S. government agencies and has entered into strategic collaborations related to vaccine development and manufacturing readiness. GeoVax does not maintain a broad portfolio of equity investments but focuses capital allocation on internal R&D programs and regulatory advancement. Its emerging technology focus remains on multi-antigen, multi-pathogen vaccine approaches leveraging its core platform.
Geographic Footprint
GeoVax Labs, Inc. is headquartered in Atlanta, Georgia, and conducts the majority of its research, development, and corporate operations in the United States. Its activities are primarily domestic, reflecting its reliance on U.S.-based government funding, regulatory pathways, and research infrastructure.
International presence is primarily indirect, arising through global clinical trials, manufacturing partnerships, and disease-focused programs targeting outbreaks in Africa, Europe, and other regions affected by emerging infectious diseases. While GeoVax does not operate foreign subsidiaries with large-scale commercial activity, its pipeline is designed for global public health application.
Leadership & Governance
GeoVax was founded by scientists with academic and government research backgrounds, and its leadership emphasizes disciplined capital management, platform-driven development, and alignment with public-sector health priorities. The company is governed by a board of directors with experience in biotechnology, government contracting, and clinical development, guiding strategy toward long-term vaccine deployment and partnership opportunities.
Key members of the executive leadership team include:
- David Dodd – President and Chief Executive Officer
- Mark Reynolds – Chief Financial Officer
- Kelly McKee – Chief Operating Officer
- Robert E. Mitchelson – Founder and Director
The leadership team’s strategic vision focuses on advancing differentiated vaccine candidates through late-stage development while leveraging government and institutional partnerships to manage risk and capital requirements.